|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Increased susceptibility for intrahepatic cholestasis of pregnancy and contraceptive-induced cholestasis in carriers of the 1331T>C polymorphism in the bile salt export pump显示文摘AIM: To study the association of three common ABCB11 and ABCC2 polymorphisms (ABCB11: 1331T>C V444A; ABCC2: 3563T>A V1188E and 4544G>A C1515Y) with intrahepatic cholestasis of pregnancy (ICP) and contraceptive-induced cholestasis (CIC). METHODS: ABCB11 and ABCC2 genotyping data were available from four CIC patients and from 42 and 33 ICP patients, respectively. Allele-frequencies of the studied polymorphisms were compared with those in healthy pregnant controls and Caucasian individuals. Furthermore, serum bile acid levels were correlated with the presence or absence of the 1331 C allele.RESULTS: The ABCB11 1331T>C polymorphism was significantly more frequent in cholestatic patients than in pregnant controls: C allele 76.2% (CI, 58.0-94.4) vs 51.3% (CI 35.8-66.7), respectively (P = 0.0007); and CC allele 57.1% (CI 36.0-78.3) vs 20% (CI 7.6-32.4), respectively (P = 0.0065). All four CIC patients were homozygous carriers of the C allele. In contrast, none of the studied ABCC2 polymorphism was overrepresented in ICP or CIC patients. Higher serum bile acid levels were found in carriers of the 1331CC genotype compared to carriers of the TT genotype.CONCLUSION: Our data support a role for the ABCB11 1331T>C polymorphism as a susceptibility factor for the ←←← development of estrogen-induced cholestasis, whereas no such association was found for ABCC2. Serum bile acid and γ-glutamyl transferase levels might help to distinguish ABCB4- and ABCB11-related forms of ICP and CIC. | Yvonne Meier Tina Zodan Carmen Lang Roland Zimmermann Gerd A Kullak-Ublick Peter J Meier Bruno Stieger Christiane Pauli-Magnus | 2008 | World Journal of Gastroenterology2008，14，1： | 20 |
| 2 | Combination drug regimens for metastatic clear cell renal cell carcinoma显示文摘Renal cell carcinomas(RCC)make up about 90%of kidney cancers,of which 80%are of the clear cell subtype.About 20%of patients are already metastatic at the time of diagnosis.Initial treatment is often cytoreductive nephrectomy,but systemic therapy is required for advanced RCC.Single agent targeted therapies are moderately toxic and only somewhat effective,leading to development of immunotherapies and combination therapies.This review identifies limitations of monotherapies for metastatic renal cell carcinoma,discusses recent advances in combination therapies,and highlights therapeutic options under development.The goal behind combining various modalities of systemic therapy is to potentiate a synergistic antitumor effect.However,combining targeted therapies may cause increased toxicity.The initial attempts to create therapeutic combinations based on inhibition of the vascular endothelial growth factor or mammalian target of rapamycin pathways were largely unsuccessful in achieving a profile of increased synergy without increased toxicity.To date,five combination therapies have been approved by the U.S.Food and Drug Administration,with the most recently approved therapies being a combination of checkpoint inhibition plus targeted therapy.Several other combination therapies are under development,including some in the phase 3 stage.The new wave of combination therapies for metastatic RCC has the potential to increase response rates and improve survival outcomes while maintaining tolerable side effect profiles. | Viraj V Khetani Daniella E Portal Mansi R Shah Tina Mayer Eric A Singer | 2020 | World Journal of Clinical Oncology2020，11，8： | 2 |
| 3 | Statin use and cognitive function in middle-aged adults with type 1 diabetes显示文摘AIM To test associations between statin use and cognitive impairment in adults with childhood-onset type 1 diabetes(T1D).METHODS In 2010-13, n = 108 middle-aged participants from ongoing observational Pittsburgh Epidemiology of Diabetes Complications Study underwent neurocognitive assessment(mean age and T1 D duration of 49 and 41 years, respectively). All were diagnosed with childhoodonset(i.e., prior to age 18) T1 D between 1950 and 1980 and were seen within one year of diagnosis at Children's Hospital of Pittsburgh. Self-reported statin use(yes/no and if yes, name of statin) was collected biennially from parent study baseline(1986-1988) to time of neurocognitive testing. Logistic regression models tested associations between statin use groups and cognitive impairment(defined as having two or more cognitive test scores 1.5SD or worse than published norms) while linear regression models tested associations between statin use groups and cognitive domain z-scores(domains: Verbal IQ, memory, executive function, psychomotor speed, and visuo-construction). All models controlled for education and age. To address confounding by indication, models were repeated using a propensity score for statin use.RESULTS Of the 108 participants, 51 reported never using statins. Median duration of statin use among the 57 ever users was 6 years. These 57 ever statin users were split to create two groups(≤ or > median years of statin use): 1-6 years(n = 25), and 7-12 years(n = 32). Compared with never users, using statins 1-6 years tripled the odds of cognitive impairment(OR = 3.16; 95%CI: 0.93-10.72; P = 0.06) and using statins 7-12 years almost quintupled the odds of cognitive impairment(OR = 4.84; 95%CI: 1.63-14.44; P = 0.005). Compared with never users, using statins 1-6 or 7-12 years was related to worse performance in the memory domain(β =-0.52; P = 0.003, and-0.39; P = 0.014, respectively). Adjusting for coronary artery disease, low density lipoprotein cholesterol, and Apo E4 status did not substantially alter results, and none of these covariates were significantly related to cognitive outcomes(all P > 0.05). Propensity score analyses support that associations between poor cognitive outcomes and statin use were not due merely to confounding by indication. CONCLUSION Statin use was associated with cognitive impairment, particularly affecting memory, in these middle-aged adults with childhood-onset T1 D, whom at this age, should not yet manifest age-related memory deficits. | Karen A Nunley Trevor J Orchard Christopher M Ryan Rachel Miller Tina Costacou Caterina Rosano | 2017 | World Journal of Diabetes2017，8，6： | 2 |
| 4 | Severe Hand, Foot, and Mouth Disease Associated with Coxsackievirus A6 - Alabama, Connecticut, California, and Nevada, November 201 1 - February 2012显示文摘 | McIntyre Mary G Stevens Kelly M Davidson Sherri Pippin Tina Magill Dagny Kulhanjian Julie A Kelly Daniel Greenhow Tara L Salas Maria L Yagi Shigeo Padilla Tasha Berumen Ricardo Glaser Carol Landry Marie Louise Lott Jason Chen Lei Paulson | 2012 | EN2012，，12： | 2 |
| 5 | Characterization of CFTR expression and chloride channel activity in human endothelia显示文摘 | Tousson A Van Tina BA Naren AP | 1998 | Am J Physiol Cell Physiol1998，275，： | 1 |
| 6 | Using NDVI to assess vegetative land cover change in central Puget sound显示文摘 | MORAWITZ D F BLEWETF TINA M COHEN A | 2006 | Enviro- nmental Monitoring and Assessment2006，114，： | 1 |
| 7 | Metabolic syndrome and its components as predictors of incident type 2 diabetes mellitus in an Aboriginal community显示文摘 | Ley Sylvia H Harris Stewart B Mamakeesick Mary Noon Tina Fiddler Edith Gittelsohn Joel Wolever Thomas M S Connelly Philip W Hegele Robert A Zinman Bernard Hanley Anthony J G | 2009 | Canadian Medical Association. Journal2009，，6： | 1 |
| 8 | Comparative study of nitrazepam metabolism in perfused isolated liver of laboratory animals显示文摘 | BARTOE I TINA K J GUAITANI A | 1970 | Eur J Pharmacol1970，11，3： | 1 |
| 9 | The institutional effects on strategic alliance partner selection in transition economics: Chinavs Russia 显示文摘 | HITT MA DAVID A TINA DEA M | 2004 | Organization Science2004，15，2： | 1 |
| 10 | Only the CIM5RA ^+ subpopula- tion of CIM ^+ CD25^bright regulatory T cells gives rise to homogeneous regu- latory T-cell lines upon in vitro expansion 显示文摘 | Hoffman P Ruediger E Tina J Bet a/ | 2006 | Blood2006，108，： | 1 |
| 11 | Mechanical Bowel Preparation in Intestfilal Surgery:A MemAnalysis and Review of the Literature显示文摘 | Carlos E Pineda Andrew A Shelton Tina Heman-dez-Boussard | 2008 | Gastrointest Surg2008，12，8： | 1 |
| 12 | Part -ner selection in emerging and developed market contexts: Re- source- based and organizational learning perspectives 显示文摘 | HITI' A MICHAEL M TINA DACIN EDWARD LEVITAS | 2000 | Academy of Management Journal2000，34，3： | 1 |
| 13 | Consequences of activating the calcium - permeable ion channel TRPVl in breast cancer cells with regulated TRPVl expression显示文摘 | Tina TL Amelia A Ping T | 2014 | Cell Calcium2014，，： | 1 |
| 14 | Confidentiality in health care: A Survey of knowledge, perceptions, and attitudes among high school students显示文摘 | Tina LC Judith A Ann LS | 1993 | JAMA1993，269，11： | 1 |
| 15 | Laparoscopic intracavitary de-bridement of peripancreatic necrosis显示文摘 | John A Thomas V Tina D | 2000 | Surgery2000，127，1： | 1 |
| 16 | Assmptomatic intestinal colonization by Clostridium difficile in preterm neonates显示文摘 | Tina LG Proto N Sciacca A | 1994 | Pediatr Infect Dis J1994，13，12： | 1 |
| 17 | Neonatal Jaundice Technologies:Phototherapy for neonatal jaundice显示文摘 | Tina M Slusher Zipursky A | | 0，，： | 1 |
| 18 | Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial显示文摘 | Susan J Dutton David R Ferry Jane M Blazeby Haider Abbas Asa Dahle-Smith Wasat Mansoor Joyce Thompson Mark Harrison Anirban Chatterjee Stephen Falk Angel Garcia-Alonso David W Fyfe Richard A Hubner Tina Gamble Lynnda Peachey Mina Davoudianfar Sarah R Pear | 2014 | Lancet Oncology2014，，8： | 1 |
| 19 | Enzymes acting on peptides containing D-amino acid显示文摘 | Yasuhisa A and Tina L L | 2000 | J Biosc and Bioeng2000，89，： | 1 |
| 20 | Maternal Correlates of Health Status in Adolescents with Inflammatory Bowel Disease显示文摘 | Mark A Lumley Michelle | 2002 | Journal of Psychosomatic Research2002，52，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员